Pioneered for pharmaceutical applications by Bend Research (now Lonza), spray drying has emerged as a primary technology for addressing poor dissolution rate, solubility and bioavailability. Spray-dried dispersions represent an established approach in bringing an increasing number of BCS II compounds to market. we have premier expertise and capability in spray drying, with integrated capabilities in place to support proof-of-concept through commercial scale manufacture of spray-dried dispersions or finished drug products based on these intermediates.
The majority of today’s drug candidates have low aqueous solubility (BCS II), and require an enabling technology to enhance oral bioavailability. Amorphous solid dispersion approaches utilizing spray dried dispersion (SDD) technology offer a proven and highly flexible approach to significantly improve the bioavailability of promising BCS ll compounds.
Spray drying is also increasingly utilized for dry powder inhaler (DPI) applications, providing particle engineered formulations in the required particle size distribution to meet target product profiles.
Our Bend (OR) site is our Center of Excellence for solid dispersions. The site is equipped with a full range of processing capabilities for spray drying, as well as hot-melt extrusion. Bend also has extensive capabilities in developing and manufacturing finished drug products in monolithic or multiparticulate formats.